hTERC基因扩增在宫颈癌及宫颈癌前病变中的临床意义  

Human telomerase RNA component gene amplification in cervical intraepithelial neoplasia and cervical cancer with fluorescence in situ hybridization and its clinical significance

作　　者：成志强[1] 王洋[1] 王晓玫[1] 俞丽娜[2] 贺黎升[1] 彭全州[1] 胡锦涛[1] 陈灼怀[1] 

机构地区：[1]深圳市人民医院病理科,广东省518020 [2]深圳市人民医院肛肠外科,广东省518020

出　　处：《中华临床医师杂志（电子版）》2014年第5期21-24,共4页Chinese Journal of Clinicians(Electronic Edition)

基　　金：深圳市科技计划资助项目(201202130)

摘　　要：目的检测hTERC基因在宫颈癌前病变及宫颈癌中的扩增情况,探讨其在宫颈癌筛查中的价值。方法采用双色荧光原位杂交技术(FISH)检测30例正常者、90例宫颈上皮内瘤变及30例宫颈癌宫颈脱落细胞hTERC基因的表达情况,以对照组的检测结果建立正常阈值。结果正常组、CIN1组、CIN2组、CIN3组和宫颈鳞癌hTERC基因阳性表达率分别为0%(0/30)、16.67%(5/30)、53.33%(16/30)、80%(24/30)、100%(30/30),随着宫颈病变级别增高,其异常表达百分率亦随之增高。结论 CIN1、CIN2、CIN3及宫颈鳞癌均有hTERC基因扩增,其拷贝数随CIN分级增加而增加。检测宫颈脱落细胞hTERC基因扩增对宫颈癌筛查及宫颈病变进展预测具有良好的临床应用空间。Objective To investigate the amplification of the human telomerase gene（hTERC） in cervical cancer and precancerous lesions of uterine cervix and its value in screening of cervical cancer. Methods Cervical cast-off cell specimens were screened from 150 out patients with cervical lesion, including normal,CIN1,CIN2,CIN3 and cervical squamous carcinoma cell from liquid based cytology （each of 30 cases） by dual-FISH technology. The results of normal control group were used to set up the threshold. Results The positive rate of hTERC gene amplification in controls, CIN1, CIN2, CIN3 and cervical squamous carcinoma was respectively 0%（0/30）, 16.67%（5/30）, 53.33%（16/30）, 80%（24/30）, 100%（30/30）, and the percentage of abnormal cells was increased with the cervical lesion degree of pathological grade. Conclusions There is an abnormal amplification of hTERC gene in CIN1, CIN2, CIN3 and cervical squamous carcinoma, and its copy numbers are increased with the serious degree of pathological grades. Therefor, it has a certain clinical space for screening cervical cancer and prediction of cervical lesion progression by detection of amplification of hTERC gene in cervical cast-off cells with FISH technology.

关 键 词：宫颈上皮内瘤样病变 原位杂交 荧光 宫颈鳞癌 HTERC基因 

分 类 号：R737.33[医药卫生—肿瘤]